Business Description
Nuwellis Inc
NAICS : 334517
SIC : 3845
ISIN : US67113Y7022
Total Employee Number:
38Description
Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.86 | |||||
Equity-to-Asset | 0.38 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -66.78 | |||||
Beneish M-Score | -0.66 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Future 3-5Y Total Revenue Growth Rate Estimate | 57.1 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.35 | |||||
9-Day RSI | 17.67 | |||||
14-Day RSI | 16.51 | |||||
3-1 Month Momentum % | -85.99 | |||||
6-1 Month Momentum % | -92.4 | |||||
12-1 Month Momentum % | -97.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.56 | |||||
Quick Ratio | 1.09 | |||||
Cash Ratio | 0.56 | |||||
Days Inventory | 232.84 | |||||
Days Sales Outstanding | 57.66 | |||||
Days Payable | 290.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -1013.1 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 65.47 | |||||
Operating Margin % | -143.85 | |||||
Net Margin % | -217.22 | |||||
EBITDA Margin % | -92.78 | |||||
FCF Margin % | -131.21 | |||||
OCF Margin % | -129.84 | |||||
ROE % | -2480.21 | |||||
ROA % | -255.55 | |||||
ROIC % | -528.31 | |||||
3-Year ROIIC % | -393.83 | |||||
ROC (Joel Greenblatt) % | -569.23 | |||||
ROCE % | -209.35 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.01 | |||||
PB Ratio | 0.08 | |||||
Price-to-Tangible-Book | 0.09 | |||||
EV-to-EBIT | 0.08 | |||||
EV-to-EBITDA | 0.09 | |||||
EV-to-Revenue | -0.08 | |||||
EV-to-Forward-Revenue | 0.07 | |||||
EV-to-FCF | 0.06 | |||||
| Price-to-Net-Current-Asset-Value | 0.15 | |||||
Earnings Yield (Greenblatt) % | 1250 | |||||
FCF Yield % | -1048.86 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NUWE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nuwellis Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 8.769 | ||
| EPS (TTM) ($) | -2243.346 | ||
| Beta | 1.9239 | ||
| 3-Year Sharpe Ratio | -1.57 | ||
| 3-Year Sortino Ratio | -1.78 | ||
| Volatility % | 173.53 | ||
| 14-Day RSI | 16.51 | ||
| 14-Day ATR ($) | 1.152371 | ||
| 20-Day SMA ($) | 3.768775 | ||
| 12-1 Month Momentum % | -97.96 | ||
| 52-Week Range ($) | 2.7501 - 908.249999 | ||
| Shares Outstanding (Mil) | 0.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nuwellis Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nuwellis Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-12 09:00 | In 124 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 123 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 09:00 | In 34 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 33 days | ||
| 0.0285714:1 Stock Split | 2026-06-26 | 3.31 (+2.16%) | ||
| First quarter earnings conference call for 2026 | 2026-05-12 09:00 | 36.40 (-2.80%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 36.40 (-2.80%) | ||
| General meeting for 2025 | 2026-04-28 14:00 | 40.60 (-2.52%) | ||
| Annual report for 2025 | 2026-03-11 | 45.50 (-7.80%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-10 09:00 | 45.15 (-7.19%) |
Show
Entries
Nuwellis Inc Frequently Asked Questions
What is Nuwellis Inc(NUWE)'s stock price today?
The current price of NUWE is $3.01. The 52 week high of NUWE is $908.25 and 52 week low is $2.75.
When is next earnings date of Nuwellis Inc(NUWE)?
The next earnings date of Nuwellis Inc(NUWE) is 2026-08-14 Est..
Does Nuwellis Inc(NUWE) pay dividends? If so, how much?
Nuwellis Inc(NUWE) does not pay dividend.
Guru Commentaries on NAS:NUWE
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Nuwellis Inc
Headlines
See More- 1
Jun 16, 2026
Nuwellis names Mike McCormick as CEO
Seeking Alpha • 7:44am
Nuwellis Appoints Mike McCormick as Chief Executive Officer
Benzinga • 7:30am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers